Skip to main content
. 2022 May 11;2:48. doi: 10.1038/s43856-022-00114-7

Fig. 5. Antibody reactivity to epitopes of melanoma-antigens is associated with immunotherapy.

Fig. 5

a Box plots showing the IgG response to peptides containing the 3 epitopes that were most differentiating for melanoma-specific immunotherapy as deemed by logistic regression model analysis. Abundance – number of IgG-bound peptides containing the epitope biomarker sequence detected in a sample. Control – healthy controls for melanoma group (CTRL-Mel, n = 80) and non-cancer controls of NSCLC group (CTRL-NSCLC, n = 10); MelVac – NSCLC patients who received MelCancerVac® vaccine (n = 6); PEM-Mel – melanoma patients receiving pembrolizumab treatment (n = 5). Two-sided Wilcoxon Rank Sum test **p < 0.01, *** p < 0.001, p-values not adjusted for multiple comparisons. b Logistic regression model of biomarkers M3, M9, and M11. AUC – area under curve; SE – standard error; CI – confidence interval.